scholarly journals Lamin B autoantibodies in sera of certain patients with systemic lupus erythematosus.

1987 ◽  
Vol 165 (3) ◽  
pp. 750-762 ◽  
Author(s):  
W H Reeves ◽  
N Chaudhary ◽  
A Salerno ◽  
G Blobel
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Antinuclear Antibody ◽  
Nuclear Lamina ◽  
Biological Functions ◽  
Systemic Lupus ◽  
Antibody Assay ◽  
Western Blots ◽  
Lamin B ◽  
Cytoplasmic Filaments

Sera from four patients with systemic lupus erythematosus containing antibodies that yield nuclear rim staining of HEp-2 cells by indirect immunofluorescence were identified and characterized. Each serum contained autoantibodies reacting strongly with lamin B on western blots. One of the four sera displayed weaker reactivity with lamins A and C, while the other three displayed only minimal reactivity with lamins A and C. Titers of antilamin antibodies ranged from 1:1,250 to 1:36,250. Two of the sera also reacted at a dilution of 1:20 with cytoplasmic filaments of PTK-2 cells, suggesting that a small fraction of the autoantibodies in these sera may bind to alpha-helical domains of the lamins that are homologous to those of intermediate filaments. The majority of the antilamin antibodies in these patients' sera are specific for portions of the lamin B molecule that are not homologous to lamins A and C, however. The findings suggest that autoantibodies to the nuclear lamina may, in some instances, be responsible for a rim pattern in the fluorescent antinuclear antibody assay. In addition, autoantibodies to the nuclear lamina in sera of certain patients with systemic lupus erythematosus may be useful for defining the molecular structure and biological functions of lamin B, as well as for studying mechanisms of autoimmunity.

scholarly journals Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort

2019 ◽  
Vol 71 (7) ◽  
pp. 893-902 ◽  
Author(s):  
May Y. Choi ◽  
Ann E. Clarke ◽  
Yvan St. Pierre ◽  
John G. Hanly ◽  
Murray B. Urowitz ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Antinuclear Antibody ◽  
Inception Cohort ◽  
Systemic Lupus

scholarly journals MAGE-B2 Autoantibody: A New Biomarker for Pediatric Systemic Lupus Erythematosus

2008 ◽  
Vol 35 (12) ◽  
pp. 2430-2438 ◽  
Author(s):  
ALICE D.C. HOFTMAN ◽  
LEI-QIAN TAI ◽  
SHEILA TZE ◽  
DAVID SELIGSON ◽  
RICHARD A. GATTI ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Activity Index ◽  
Disease Activity Index ◽  
Systemic Lupus ◽  
Western Blots ◽  
Pediatric Systemic Lupus Erythematosus ◽  
Embryonic Antigen ◽  
Pediatric Sle

ObjectiveMelanoma-associated antigen gene B2 (MAGE-B2) encodes an embryonic antigen normally silenced after birth except in testis and placenta. We identified the MAGE-B2 gene and autoantibodies in pediatric patients with systemic lupus erythematosus (SLE) glomerulonephritis. We investigated the prevalence of MAGE-B2 autoantibodies in association with active SLE, to determine a pathogenetic role of MAGE-B2 protein through its distribution in cells and tissues.MethodsAcross-sectional study analyzed the frequency of MAGE-B2 autoantibodies in 40 patients with pediatric SLE, 23 adult controls, and 16 patients with pediatric juvenile rheumatoid arthritis (JRA) using Western blots containing recombinant MAGE-B2. SLE Disease Activity Index 2000 (SLEDAI-2K) and British Isles Lupus Assessment Group (BILAG) index measured SLE disease activity. Tissue distribution of MAGE-B2 protein was assessed by immunohistochemistry, immunofluorescence, and Western blots.ResultsSeventeen (43%) of 40 pediatric SLE patients had MAGE-B2 autoantibodies as compared to 0 of 16 JRA patients and 2 of 23 adult controls. SLE disease activity was significantly higher in MAGE-B2 autoantibody-positive versus autoantibody-negative patients (SLEDAI-2K, mean 10.9 vs 5.2, p = 0.013; BILAG, mean 15.3 vs 6.3, p = 0.023). Active nephritis was more prevalent (60% vs 24%) inMAGE-B2 autoantibody-positive than autoantibody-negative SLE patients. MAGE-B2 protein was visualized in SLE kidney proximal convoluted tubules and in tumor epithelial cells, but not in lymphoblastoid cells.ConclusionMAGE-B2 autoantibody appears to be a clinically relevant biomarker for pediatric SLE disease activity and nephritis.

scholarly journals Exposure of HEp-2 Cells to Stress Conditions Influences Antinuclear Antibody Reactivity

2002 ◽  
Vol 9 (2) ◽  
pp. 287-294 ◽  
Author(s):  
Liping Du ◽  
Sachiko Fukushima ◽  
Annahita Sallmyr ◽  
Rolf Manthorpe ◽  
Anders Bredberg
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Dna Damage ◽  
Lupus Erythematosus ◽  
Antinuclear Antibody ◽  
Nuclear Protein ◽  
Optimal Conditions ◽  
Healthy Individuals ◽  
Systemic Lupus ◽  
Lower Reactivity ◽  
Stressed Cells

ABSTRACT This study of stress-related antinuclear antibody (ANA) reactivity was undertaken with the objective of improving clinical ANA testing. ANA was determined by parallel enzyme-linked immunosorbent assays of crude nuclear protein antigen extracted from HEp-2 cells either grown under optimal conditions (providing nonstress ANA antigen) or exposed to stress (providing stress ANA antigen). The stress stimuli used were gamma radiation (causing DNA damage) and a hypertonic environment (causing apoptosis). Signs of stress-related ANA reactivity were seen among connective tissue disease (CTD) patients (including patients with systemic lupus erythematosus; mixed CTD; calcinosis, Reynaud's phenomenon, esophageal motility disorders, sclerodactyly, and telangiectasia; scleroderma; and Sjögren's syndrome): 11% showed stress-positive ANA (i.e., a significantly stronger ANA reactivity with the extract from stressed cells), whereas 21% showed a markedly weaker reaction with the stress antigen. In contrast, among ANA screening patient sera, with no diagnosis of CTD, the fraction showing stress-positive ANA was higher (7 to 8%, depending on the type of stress) than among those showing a lower reactivity with stress antigen (1.5 to 2.5%). Only one serum among 89 (1%) tested sera from healthy individuals showed a stress-related ANA reaction. This demonstration of stress-related ANA suggests a means to improve the performance of clinical ANA testing.

Childhood systemic lupus erythematosus with negative antinuclear antibody test

1981 ◽  
Vol 98 (4) ◽  
pp. 578-581 ◽  
Author(s):  
J.P. Gillespie ◽  
C.B. Lindsley ◽  
M.A. Linshaw ◽  
W.P. Richardson
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Antinuclear Antibody ◽  
Antibody Test ◽  
Systemic Lupus

Seroconversion to antinuclear antibody negativity and its association with disease flare in patients with systemic lupus erythematosus

Lupus ◽  
2020 ◽  
Vol 29 (7) ◽  
pp. 697-704 ◽  
Author(s):  
Oh Chan Kwon ◽  
Yong-Gil Kim ◽  
Jung Hwan Park ◽  
Min-Chan Park
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Antinuclear Antibody ◽  
Antinuclear Antibodies ◽  
Cox Regression ◽  
British Isles ◽  
Systemic Lupus ◽  
Free Survival ◽  
Cox Regression Analysis ◽  
Kaplan Meier

Objective To evaluate the rate of seroconversion to antinuclear-antibody negativity in patients with systemic lupus erythematosus and its association with subsequent systemic lupus erythematosus flare risk. Methods Medical records of patients with systemic lupus erythematosus with positive antinuclear antibodies (titer ≥1 : 40) at diagnosis and at least one repeat antinuclear antibody test were reviewed. We determined the frequency of seroconversion to antinuclear antibody negativity among these patients and investigated whether seroconversion to antinuclear antibody negativity was associated with subsequent systemic lupus erythematosus flare risk. The seroconversion to antinuclear antibody negativity was defined as a conversion of positive antinuclear antibodies to a titer below the cut-off of 1 : 40. Systemic lupus erythematosus flare was defined as one new British Isles Lupus Assessment Group A or two new British Isles Lupus Assessment Group B domain scores. To estimate hazard ratios and 95% confidence intervals for systemic lupus erythematosus flare according to seroconversion to antinuclear antibody negativity, Cox regression analysis with adjustment for known systemic lupus erythematosus flare risk factors was performed. Kaplan-Meier analysis was used to compare flare-free survival rates between negative converters and non-converters. Results Among the total 175 patients, seroconversion to antinuclear antibody negativity was found in 17 (9.7%) patients in a median 53.5 (range: 25.7–84.0) months. After the last antinuclear antibody tests, 53 systemic lupus erythematosus flare cases were identified during 14.3 (range: 8.2–21.7) months of follow-up. Systemic lupus erythematosus flare risk was significantly lower in patients with negatively seroconverted antinuclear antibodies (adjusted hazard ratio 0.13, 95% confidence interval 0.03–0.58, p = 0.007). Kaplan-Meier analysis showed significantly higher flare-free survival in negative converters than in non-converters ( p = 0.004). Conclusion Seroconversion to antinuclear antibody negativity occurred in 9.7% of patients over 53.5 months and was associated with a lower future systemic lupus erythematosus flare risk.

scholarly journals Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities

2018 ◽  
Vol 78 (8) ◽  
pp. e76-e76 ◽  
Author(s):  
Philippe Willems ◽  
Ellen De Langhe ◽  
René Westhovens ◽  
Steven Vanderschueren ◽  
Daniel Blockmans ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Antinuclear Antibody ◽  
Systemic Lupus ◽  
Entry Criterion
Sign in / Sign up

Export Citation Format

Share Document